Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC)

Table 3 Proportion of AEFIs during the 7 days following vaccination

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Tenderness/swelling or erythema
Absent	59.9	64,3	76,4	86,6	91,1	94,9	96,2
Mild	38.8	34,4	22,9	12,7	8,3	4,5	3,2
Severe	1.3	1,3	0,6	0,6	0,6	0,6	0,6
Refusal to move the extremity
Absent	58,6	62,4	80,3	90.4	96.2	98.7	98.7
Mild	29,3	29,9	17.8	8.9	3.2	0.6	1.2
Severe	12,1	7,6	1.9	0.6	0.6	0.6	0.0
Unusual crying
Absent	59.9	77.7	90.5	93.0	95.5	97.4	96.8
Mild	38.9	19.8	8.3	6.4	4.5	2.6	3.2
Severe	1.3	2.6	1.3	0.6	0.0	0.0	0.0
Fever
Absent	66.2	84.1	96.2	94.9	97.4	97.5	96.8
Mild (< 38.5 °C)	29.9	15.3	3.2	4.5	1.9	1.3	2.6
Severe (> 38.5 °C)	3.8	0.6	0.6	0.6	0.6	1.3	0.6
Hypotonia
Absent	92.4	96.8	98.7	98.1	99.4	99.4	99.4
Mild	7.0	3.2	1.3	1.9	0.6	0.6	0.6
Severe	0.6	0.0	0.0	0.0	0.0	0.0	0.0
Hypo-responsiveness
Absent	96.2	98.1	98.1	98.7	0.0	0.0	0.0
Mild	0.3	1.9	1.9	1.3	0.0	0.0	0.0
Severe	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Urticaria/angioedema
Absent	99.4	98.1	98.1	99.4	0.0	0.0	0.0
Mild	0.6	1.9	1.9	0.6	0.0	0.0	0.0
Severe	0.0	0.0	0.0	0.0	0.0	0.0	0.0

ISSN: 1824-7288